AI Portfolio Summary
In 2025 Q4, Vestal Point Capital, LP maintained a portfolio of 105 distinct positions. The most significant new addition to the portfolio was Invesco QQQ Trust Se, which now represents 7.31% of the total fund value. They heavily accumulated shares in Abivax SA, increasing their position by 90.0%. Conversely, Vestal Point Capital, LP completely exited their position in Amicus Therapeutics .
Total Positions
105
Quarter
2025 Q4
Top Holding
ABVX (8.7%)
Top 10 Concentration
50.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 105
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ABVX
Abivax SA
|
Healthcare | 8.71% | 3.83% |
#1
3
Prev: #4
|
8.5 | 900,000 | 90.0% |
P
S
|
1,900,000 | $256,224,500 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QQQ
PUT
Invesco QQQ Tru...
|
PUT Option | 7.31% | — |
#2
Prev: #—
|
7.9 | 350,000 | no change |
NEW
|
350,000 | $215,008,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
Arcellx Inc
|
Healthcare | 6.48% | 4.63% |
#3
1
Prev: #2
|
6.6 | 1,675,000 | 134.0% |
P
S
|
2,925,000 | $190,710,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
Terns Pharmaceu...
|
Healthcare | 6.18% | — |
#4
Prev: #—
|
6.5 | 4,500,000 | no change |
NEW
|
4,500,000 | $181,800,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMRN
BioMarin Pharma...
|
Healthcare | 6.06% | 2.03% |
#5
11
Prev: #16
|
5.9 | 2,170,000 | 261.4% |
P
S
|
3,000,000 | $178,290,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GMED
Globus Medical ...
|
Healthcare | 3.78% | 3.23% |
#6
2
Prev: #8
|
2.0 | 25,000 | 2.0% |
P
S
|
1,275,000 | $111,320,250 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
Nurix Therapeut...
|
Healthcare | 3.02% | 1.45% |
#7
20
Prev: #27
|
3.7 | 1,215,000 | 35.0% |
P
S
|
4,690,000 | $88,969,300 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALC
Alcon AG
|
Healthcare | 2.96% | 3.70% |
#8
3
Prev: #5
|
1.7 | 5,000 | 0.5% |
P
S
|
1,105,000 | $87,085,050 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DXCM
Dexcom Inc
|
Healthcare | 2.88% | 1.98% |
#9
9
Prev: #18
|
4.2 | 625,000 | 96.2% |
P
S
|
1,275,000 | $84,621,750 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRK
Merck & Co Inc
|
Healthcare | 2.77% | — |
#10
Prev: #—
|
4.6 | 775,000 | no change |
NEW
|
775,000 | $81,576,500 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
Taysha Gene The...
|
Healthcare | 2.57% | 0.81% |
#11
33
Prev: #44
|
4.0 | 8,250,000 | 150.0% |
P
S
|
13,750,000 | $75,625,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABT
Abbott Laborato...
|
Healthcare | 2.56% | 1.51% |
#12
13
Prev: #25
|
4.0 | 350,000 | 140.0% |
P
S
|
600,000 | $75,174,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMTX
Immatics NV
|
Healthcare | 2.19% | 2.44% |
#13
Prev: #13
|
1.4 | -225,000 | -3.5% |
P
S
|
6,125,000 | $64,312,500 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TYRA
Tyra Bioscience...
|
Healthcare | 2.17% | 1.53% |
#14
10
Prev: #24
|
1.9 | no change | no change |
P
S
|
2,425,000 | $63,753,250 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAX
Bicara Therapeu...
|
Healthcare | 2.05% | 3.64% |
#15
9
Prev: #6
|
0.8 | -1,525,000 | -29.9% |
P
S
|
3,575,000 | $60,167,250 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARWR
Arrowhead Pharm...
|
Healthcare | 2.03% | — |
#16
Prev: #—
|
4.3 | 900,000 | no change |
NEW
|
900,000 | $59,751,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELVN
Enliven Therape...
|
Healthcare | 2.01% | 1.07% |
#17
17
Prev: #34
|
3.8 | 2,670,000 | 230.2% |
P
S
|
3,830,000 | $58,982,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
Disc Medicine I...
|
Healthcare | 1.98% | 1.49% |
#18
8
Prev: #26
|
3.3 | 235,000 | 47.0% |
P
S
|
735,000 | $58,366,350 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JAZZ
Jazz Pharmaceut...
|
Healthcare | 1.68% | 2.98% |
#19
9
Prev: #10
|
0.7 | -210,000 | -42.0% |
P
S
|
290,000 | $49,300,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DAWN
Day One Biophar...
|
Healthcare | 1.65% | 0.85% |
#20
21
Prev: #41
|
3.7 | 2,525,000 | 94.4% |
P
S
|
5,200,000 | $48,464,000 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LXEO
Lexeo Therapeut...
|
Healthcare | 1.51% | 0.97% |
#21
18
Prev: #39
|
3.1 | 1,225,000 | 37.7% |
P
S
|
4,475,000 | $44,436,750 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANRO
Alto Neuroscien...
|
Healthcare | 1.50% | 0.17% |
#22
47
Prev: #69
|
3.6 | 1,535,000 | 161.6% |
P
S
|
2,485,000 | $44,233,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
Apogee Therapeu...
|
Healthcare | 1.41% | 0.76% |
#23
22
Prev: #45
|
3.1 | 125,000 | 29.4% |
P
S
|
550,000 | $41,514,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
Olema Pharmaceu...
|
Healthcare | 1.40% | — |
#24
Prev: #—
|
4.1 | 1,650,000 | no change |
NEW
|
1,650,000 | $41,250,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
Axsome Therapeu...
|
Healthcare | 1.30% | 0.82% |
#25
18
Prev: #43
|
3.0 | 60,000 | 40.0% |
P
S
|
210,000 | $38,354,400 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FOLD
Amicus Therapeu...
|
Healthcare | 0.00% | 3.47% |
Sold All 😨
(Was: #7) |
0.0 | -9,750,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
Ionis Pharmaceu...
|
Healthcare | 0.00% | 3.18% |
Sold All 😨
(Was: #9) |
0.0 | -1,075,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BDX
Becton Dickinso...
|
Healthcare | 0.00% | 2.75% |
Sold All 😨
(Was: #11) |
0.0 | -325,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
Dianthus Therap...
|
Healthcare | 0.00% | 2.10% |
Sold All 😨
(Was: #15) |
0.0 | -1,180,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
Cytokinetics In...
|
Healthcare | 0.00% | 1.80% |
Sold All 😨
(Was: #19) |
0.0 | -725,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIIB
Biogen Inc
|
Healthcare | 0.00% | 1.74% |
Sold All 😨
(Was: #20) |
0.0 | -275,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
Cidara Therapeu...
|
Healthcare | 0.00% | 1.73% |
Sold All 😨
(Was: #21) |
0.0 | -400,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATXS
Astria Therapeu...
|
Healthcare | 0.00% | 1.63% |
Sold All 😨
(Was: #22) |
0.0 | -4,956,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRNX
Crinetics Pharm...
|
Healthcare | 0.00% | 1.41% |
Sold All 😨
(Was: #28) |
0.0 | -750,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DHR
Danaher Corp
|
Healthcare | 0.00% | 1.34% |
Sold All 😨
(Was: #31) |
0.0 | -150,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BLTE
Belite Bio Inc
|
Healthcare | 0.00% | 1.04% |
Sold All 😨
(Was: #36) |
0.0 | -312,500 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
Ultragenyx Phar...
|
Healthcare | 0.00% | 1.02% |
Sold All 😨
(Was: #37) |
0.0 | -750,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BRKR
Bruker Corp
|
Healthcare | 0.00% | 0.65% |
Sold All 😨
(Was: #47) |
0.0 | -440,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REGN
Regeneron Pharm...
|
Healthcare | 0.00% | 0.63% |
Sold All 😨
(Was: #48) |
0.0 | -25,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
uniQure NV
|
Healthcare | 0.00% | 0.59% |
Sold All 😨
(Was: #49) |
0.0 | -225,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BHVN
PUT
Biohaven Ltd
|
PUT Option | 0.00% | 0.48% |
Sold All 😨
(Was: #51) |
0.0 | -701,700 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSP
Inspire Medical...
|
Healthcare | 0.00% | 0.45% |
Sold All 😨
(Was: #52) |
0.0 | -135,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLT
Applied Therape...
|
Healthcare | 0.00% | 0.39% |
Sold All 😨
(Was: #55) |
0.0 | -14,250,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG Oncology Inc
|
Healthcare | 0.00% | 0.32% |
Sold All 😨
(Was: #56) |
0.0 | -175,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TVRD
Tvardi Therapeu...
|
Healthcare | 0.00% | 0.29% |
Sold All 😨
(Was: #58) |
0.0 | -167,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTYX
Ventyx Bioscien...
|
Healthcare | 0.00% | 0.29% |
Sold All 😨
(Was: #59) |
0.0 | -2,050,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GSK
GSK PLC
|
Healthcare | 0.00% | 0.24% |
Sold All 😨
(Was: #61) |
0.0 | -125,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EXAS
Exact Sciences ...
|
Healthcare | 0.00% | 0.19% |
Sold All 😨
(Was: #66) |
0.0 | -75,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ESTA
Establishment L...
|
Healthcare | 0.00% | 0.19% |
Sold All 😨
(Was: #67) |
0.0 | -100,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KOD
Kodiak Sciences...
|
Healthcare | 0.00% | 0.18% |
Sold All 😨
(Was: #68) |
0.0 | -250,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARQT
Arcutis Biother...
|
Healthcare | 0.00% | 0.17% |
Sold All 😨
(Was: #70) |
0.0 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RCUS
Arcus Bioscienc...
|
Healthcare | 0.00% | 0.15% |
Sold All 😨
(Was: #71) |
0.0 | -250,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LUNG
Pulmonx Corp
|
Healthcare | 0.00% | 0.06% |
Sold All 😨
(Was: #78) |
0.0 | -830,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRAW
Traws Pharma In...
|
Healthcare | 0.00% | 0.01% |
Sold All 😨
(Was: #81) |
0.0 | -150,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 105 holdings